Spleen & Thymus Peptides: Immune System Bioregulators Research Guide
Research overview of thymic and splenic peptide bioregulators — Thymosin Alpha-1, Thymalin, Splenin, Thymulin, and Khavinson's organ-specific peptide bioregulators. Immune modulation mechanisms, T-cell maturation, clinical applications in immune deficiency and aging, and research protocols.
TL;DR
- Thymosin Alpha-1 (Tα1): the most clinically validated thymic peptide — approved globally for viral hepatitis; 1.6mg 2x/week standard research dose
- Thymalin: Khavinson's thymic bioregulator — 10-20mg/day IM for 10-day course protocols
- Thymulin: zinc-dependent thymic hormone that declines with age; zinc supplementation partially compensates
- Splenin: splenic bioregulator targeting lymphocyte and NK cell function
- Thymic involution with age is a primary driver of immunosenescence — reversing it is a key longevity target
Disclaimer: For educational and research purposes only — not medical advice.
The thymus and spleen are primary lymphoid organs — the thymus produces educated T-cells, the spleen filters blood and coordinates immune responses. Both undergo age-related decline that contributes to immunosenescence and reduced ability to mount effective immune responses against pathogens, cancer cells, and aberrant self-tissue. Peptide bioregulators targeting these organs represent a distinct approach to immune restoration and longevity research.
The Thymus: Central T-Cell Education
The thymus is a bilobate gland located in the anterior chest. Its function:
- Receives naive T-cells from bone marrow (T-cell precursors)
- Positive selection: T-cells that can recognize self-MHC survive
- Negative selection: T-cells that react too strongly to self-antigens are deleted (preventing autoimmunity)
- Produces mature naïve T-cells for peripheral immune surveillance
Thymic involution: Progressive replacement of thymic cortex by adipose tissue. Output of new T-cells declines 2-3% per year in adults. Consequence: peripheral T-cell pool diversifies less over time; old clonal expansions (from past infections) crowd out capacity for new responses.
Thymosin Alpha-1 (Tα1)
Origin: Fraction 5 of thymosin mixture, identified and sequenced by Allan Goldstein's group in the 1970s. Synthetic version (Zadaxin) developed for pharmaceutical use.
Mechanism:
- Activates TLR9 on dendritic cells → enhanced innate immune signaling
- Promotes Th1 cytokine profile (IFN-γ, IL-2) over Th2
- Enhances NK cell cytotoxicity
- Supports T-cell maturation and activation
- Upregulates MHC class II expression on antigen-presenting cells
Clinical evidence:
- Approved in 37+ countries for hepatitis B (improves viral clearance rates)
- Phase 3 data for hepatitis C (combination with interferon)
- Sepsis/critical illness: improves outcomes in immunosuppressed patients
- Cancer adjunct: improves immune function during chemotherapy-induced immunosuppression
Research doses:
- 1.6mg SubQ 2x/week (standard oncology and hepatitis protocol)
- 900mcg/day 5 days/week in some immune restoration protocols
- Courses typically 6-12 months for chronic immune conditions
Thymalin (Khavinson Bioregulator)
Composition: Short peptide complex (tetrapeptide active component: Thr-Glu-Lys-Asp) isolated from bovine thymus; later synthesized as Thymogen.
Research protocol: 10-20mg/day intramuscular injection for 10-day course, repeated annually or semi-annually. Designed to restore T-cell counts and immune surveillance in aging individuals and immunocompromised patients.
Evidence: Khavinson group research (primarily observational/longitudinal Russian studies) shows:
- Increased T-lymphocyte counts after courses
- Reduced infectious morbidity in elderly subjects
- Improved response to vaccination
- Potential cancer surveillance benefits with annual courses
Thymulin
Thymulin is a metallopeptide (nonapeptide bound to zinc) naturally secreted by the thymus. It requires zinc for biological activity and declines significantly with age — paralleling both thymic involution and age-related zinc deficiency.
Zinc-thymulin connection: Zinc supplementation partially restores circulating thymulin activity in zinc-deficient elderly individuals. This provides mechanistic support for zinc supplementation (15-30mg/day) as a thymic support intervention — particularly in older researchers with known zinc deficiency.
Splenin (Splenic Bioregulator)
Origin: Khavinson group peptide complex from bovine spleen.
Mechanism: Modulates lymphocyte proliferation and NK cell function through gene-regulatory peptide mechanisms.
Applications: Studied in combination with Thymalin for comprehensive immune restoration; also used in cancer immunotherapy adjunct protocols in Eastern European clinical practice.
Protocol: Typically combined with Thymalin in 10-day courses; doses of 5-10mg/day IM.
Research Protocol: Immune Restoration Stack
| Compound | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Thymosin Alpha-1 | 1.6mg | SubQ | 2x/week | 6-12 months |
| Thymalin | 10-20mg | IM | Daily | 10-day course, 1-2x/year |
| Zinc Bisglycinate | 15-30mg | Oral | Daily | Ongoing |
| Vitamin D3 | 2000-5000 IU | Oral | Daily | Ongoing |
Note on Vitamin D: Vitamin D receptors are expressed on virtually all immune cells; D3 deficiency impairs T-cell function, NK cell activity, and innate immune responses. Optimizing 25(OH)D (target 50-80 ng/mL) is a foundational immune support measure before considering peptide interventions.
Frequently Asked Questions
Q: Can thymic peptides cause autoimmunity by over-stimulating the immune system? A: This is a reasonable theoretical concern. In practice, Thymosin Alpha-1 and Thymalin appear to be immune modulators rather than simple stimulators — they enhance appropriate immune responses while supporting regulatory T-cell (Treg) function that prevents autoimmunity. Clinical use of Tα1 in immunosuppressed patients has not shown increased autoimmune events. However, individuals with existing autoimmune conditions should approach thymic peptides with caution and physician oversight.
Q: Is there overlap between thymic peptide research and the TRIIM trial? A: Yes — the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) trial (Fahy et al., 2019) showed that a combination of recombinant GH, DHEA, and Metformin partially regenerated thymic tissue (as measured by MRI) in older men, reversing ~1.5 years of epigenetic aging. This shows thymic regeneration is achievable through systemic hormonal intervention. Thymic peptides approach the same goal from the opposite direction — supplementing thymic output rather than regenerating the gland itself. These approaches may be complementary.
Use the Stack Builder Calculator → /calculators/stack
For educational and research purposes only. Not medical advice.
Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.
Written by the Peptide Performance Calculator Research Team
Our team compiles research guides based on published literature for educational purposes. All content is for research use only — not medical advice. Read our disclaimer.
Frequently Asked Questions
What is Thymosin Alpha-1 and what is its research basis?
Thymosin Alpha-1 (Tα1, Zadaxin) is a 28-amino acid peptide naturally secreted by the thymus gland that promotes T-cell maturation, differentiation, and function. It has the strongest human evidence among thymic peptides — approved in 37 countries for hepatitis B and C, studied in sepsis, and used in oncology for immune restoration. It activates dendritic cells through TLR9 signaling, promotes Th1 immune responses, and enhances NK cell activity. Research doses: 1.6mg subcutaneously 2x/week for immune enhancement; higher doses used in clinical contexts.
What are Khavinson's peptide bioregulators and how do the thymic/splenic versions work?
Prof. Vladimir Khavinson's group developed a family of short regulatory peptides (2-4 amino acids) extracted from bovine organs and later synthesized. Thymalin (from thymus) and Splenin (from spleen) are the immune-targeted members of this family. They act as gene-expression regulators — binding to gene promoter regions and modulating transcription of proteins involved in their source organ's function. Thymalin promotes T-lymphocyte maturation and immune surveillance; Splenin affects lymphocyte and NK cell activity. These have been used in clinical settings in Russia and Eastern Europe for immune deficiency, aging, and cancer adjunct therapy.
How does the thymus shrink with age and why does it matter?
The thymus is responsible for T-cell education — naive T-cells from bone marrow travel to the thymus where they undergo positive and negative selection, producing competent, self-tolerant T-cells. The thymus undergoes progressive involution (shrinkage) beginning in adolescence, with functional thymic tissue replaced by fat. By age 65, thymic output of new T-cells is reduced to ~2% of peak levels. This thymic involution is a primary driver of immunosenescence (age-related immune decline), reduced vaccine responsiveness, and reduced cancer immune surveillance. Thymic peptides aim to restore or compensate for declining thymic output.
New compound guides and calculator updates — no spam, unsubscribe any time.
Free Peptide Calculators
7 free calculators covering reconstitution, dosage, syringe units, half-life, injection volume, stack planning, and cycle duration — no account needed.